Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis

Review of 140 RCTs (n=51,749) found that compared to placebo, infliximab, ixekizumab, risankizumab, bimekizumab, guselkumab, secukinumab and brodalumab were the best choices for achieving PASI 90 in people with moderate‐to‐severe psoriasis

Source:

Cochrane Database of Systematic Reviews